TCT 2018 | ULTIMATE: IVUS Guided DES Implantation for All Vessels, for All Lesions

Intravascular Ultrasound (IVUS) guided drug eluting stent (DES) implantation is associated with less adverse events compared against angiography guided stenting. This is especially clear for certain populations (with left main PCI as paradigmatic) but not so clear when dealing with all comers.

TCT 2018 | ULTIMATE: Implante de DES guiado por IVUS, para todos los vasos, para todas las lesiones1448 all comer patients requiring DES stenting were randomized 1:1 to IVUS guided vs. angiography guided procedures.  Primary end point at 12 months was a composite of cardiac death, target vessel myocardial infarction or clinically driven target vessel revascularization. The procedure was considered successful if all IVUS optimal implantation criteria were met.

 

At 12 months, there was 2.9% events rate in the IVUS group vs 5.4% in the angiography guided group (p=0.019). These events happen in only 1.6% of patients who complied with optimal implantation criteria by IVUS. If one criterion was not met, the figure would rise to 4.4% (p=0.029).


Read also: TCT 2018 | SYNTAXES: 10 Year Follow Up is ‘Trendy’.


There was also significant reduction of target vessel revascularization and definite thrombosis.

 

IVUS was shown to reduce events in an unselected population of patients, and not only in complex PCI.

 

Original title: Intravascular Ultrasound-Guided Versus Angiography-Guided Implantation of Drug- Eluting Stent in All-Comers: The ULTIMATE trial.

Presenter: Junjie Zhang.

 

ULTIMATE-presentación

ULTIMATE-artículo-original


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...